LAUSR

BACKGROUND Volatile anesthetic agents are described as rescue therapy for children invasively ventilated for critical asthma. Yet, data are currently limited to case series. AIMS Using the Virtual Pediatric Systems database, we assessed children admitted to a pediatric intensive care unit invasively ventilated for life-threatening asthma and hypothesized ventilation duration and mortality rates would be lower for subjects exposed to volatile anesthetics compared to those without exposure. METHODS We performed a retrospective, multicenter cohort study among nine institutions including children 5-17 years of age invasively ventilated for asthma from 2013 through 2019 with and without exposure to volatile anesthetics. Primary outcomes were ventilation duration and mortality. Secondary outcomes included patient characteristics, length of stay, and anesthetic related adverse events. A subgroup analysis was performed evaluating children intubated ≥2 days. RESULTS Of 203 children included for study, there were 29 (14.3%) with and 174 (85.7%) without exposure to volatiles. No differences in odds of mortality (1.1, 95% CI: 0.3-3.9, P>0.999) were observed. Those receiving volatiles experienced greater median difference in length of stay (4.8, 95% CI: 1.9-7.8 days, P<0.001), ventilation duration (2.3, 95% CI: 1-3.3 days, P<0.001), and odds of extracorporeal life support (9.1, 95% CI: 1.9-43.2, P=0.009) than subjects without volatile exposure. For those ventilated ≥2 days, no differences were detected in mortality, ventilation duration, length of stay, arrhythmias, or acute renal failure. However, the odds of extracorporeal life support remained greater for those receiving volatiles (7.6, 95% CI: 1.3-44.5, P=0.027). No children experienced malignant hyperthermia or hepatic failure after volatile exposure. CONCLUSIONS For intubated children for asthma, no differences in mechanical ventilation duration or mortality between those with and without volatile anesthetic exposure were observed. Although volatiles may represent a viable rescue therapy for severe cases of asthma, definitive, prospective trials are still needed.